Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AVI Pox
- Development stage
- Unknown
- Lead developer
- Laprovet
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intradermal
01
Overview
AVI Pox is a live, freeze-dried veterinary vaccine containing the Cutter strain of the Fowl Pox virus. It is developed by Laprovet (a subsidiary of Ceva Animal Health) and marketed by Navana Pharmaceuticals. The vaccine is indicated for the active immunization of healthy chickens and turkeys to prevent fowl pox, a viral disease characterized by proliferative lesions on the skin (cutaneous form) or upper respiratory and digestive tracts (diphtheritic form). It is typically administered via the wing-web stab method to birds between 4 and 16 weeks of age.
- Brand names
- AVI Pox
- Other names
- AVI POXFowl Pox Vaccine (Live)fowl pox vaccine
Beyond the preview
Go deeper on AVI Pox.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AVI Pox.